Histone deacetylase inhibition leads to dose-dependent suppression of oncogene-associated super-enhancers

A poster presentation for the American Society for Biochemistry & Molecular Biology Experimental Biology meeting on my contribution to Sanchez et al. (2018).

Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers

Histone deacetylase inhibitors prefererentially suppress expression super-enhancer-driven genes, which are associated with cancer.